JP6618525B2 - ピラゾール類 - Google Patents

ピラゾール類 Download PDF

Info

Publication number
JP6618525B2
JP6618525B2 JP2017508553A JP2017508553A JP6618525B2 JP 6618525 B2 JP6618525 B2 JP 6618525B2 JP 2017508553 A JP2017508553 A JP 2017508553A JP 2017508553 A JP2017508553 A JP 2017508553A JP 6618525 B2 JP6618525 B2 JP 6618525B2
Authority
JP
Japan
Prior art keywords
methyl
pyrazole
pyrazol
phenyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017508553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525700A (ja
JP2017525700A5 (enExample
Inventor
シンドラー，ルドルフ
ランカウ，ハンス−ヨアヒム
ホーフゲン，ノルベルト
グルンヴァルド，クリスティアン
エゲルランド，ウテ
ランゲン，バルバラ
ドスト，リタ
ヘイグ，トルステン
ヴァルド，シモン
Original Assignee
ヤンセン ファーマシューティカルズ，インコーポレーテッド
ヤンセン ファーマシューティカルズ，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ，インコーポレーテッド, ヤンセン ファーマシューティカルズ，インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ，インコーポレーテッド
Publication of JP2017525700A publication Critical patent/JP2017525700A/ja
Publication of JP2017525700A5 publication Critical patent/JP2017525700A5/ja
Application granted granted Critical
Publication of JP6618525B2 publication Critical patent/JP6618525B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017508553A 2014-08-15 2015-08-14 ピラゾール類 Active JP6618525B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462037815P 2014-08-15 2014-08-15
US62/037,815 2014-08-15
US201562146629P 2015-04-13 2015-04-13
US62/146,629 2015-04-13
PCT/US2015/045413 WO2016025918A1 (en) 2014-08-15 2015-08-14 Pyrazoles

Publications (3)

Publication Number Publication Date
JP2017525700A JP2017525700A (ja) 2017-09-07
JP2017525700A5 JP2017525700A5 (enExample) 2018-09-20
JP6618525B2 true JP6618525B2 (ja) 2019-12-11

Family

ID=54261065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017508553A Active JP6618525B2 (ja) 2014-08-15 2015-08-14 ピラゾール類

Country Status (9)

Country Link
US (2) US10155727B2 (enExample)
EP (1) EP3180315B1 (enExample)
JP (1) JP6618525B2 (enExample)
DK (1) DK3180315T3 (enExample)
ES (1) ES2791252T3 (enExample)
HU (1) HUE049278T2 (enExample)
PL (1) PL3180315T3 (enExample)
PT (1) PT3180315T (enExample)
WO (1) WO2016025918A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
LT3319963T (lt) 2015-07-09 2020-03-25 Janssen Pharmaceutica Nv Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
CA3014314A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
US10487055B2 (en) 2016-06-01 2019-11-26 Rhode Island Board Of Education Diindole compounds useful in treatment of nervous system disorders
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
US11447503B2 (en) 2019-06-14 2022-09-20 Janssen Pharmaceutica Nv Pyridine carbamates and their use as GLUN2B receptor modulators
WO2019193516A2 (en) * 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
BR112021025141A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Pirazolo-piridinas heteroaromáticas substituídas e seu uso como moduladores do receptor glun2b
KR20220024403A (ko) 2019-06-14 2022-03-03 얀센 파마슈티카 엔.브이. 치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
CN113993583A (zh) 2019-06-14 2022-01-28 詹森药业有限公司 取代的吡唑并[4,3-b]吡啶及其作为GLUN2B受体调节剂的用途
US11459336B2 (en) 2019-06-14 2022-10-04 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
PH12021552839A1 (en) 2019-06-14 2022-10-03 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
EP3983075A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610723B2 (en) 2001-01-29 2003-08-26 Hoffmann-La Roche Inc. Imidazole derivatives
KR20040111445A (ko) 2002-03-28 2004-12-31 에자이 가부시키가이샤 신경퇴행성 질환 치료용 ｃ─Ｊｕｎ Ｎ─말단 키나아제억제제로서의 ７─아자인돌
EP1720860A1 (en) 2004-02-18 2006-11-15 AstraZeneca AB Triazole compounds and their use as metabotropic glutamate receptor antagonists
WO2007065655A1 (en) 2005-12-07 2007-06-14 Neurosearch Sweden Ab Disubstituted phenylpiperidines as modulators of cortical catecholaminergic neurotransmission
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
NZ581127A (en) * 2007-05-25 2012-06-29 Abbott Gmbh & Co Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
US20100227846A1 (en) 2007-08-30 2010-09-09 Takeda Pharmaceutical Company Limited Substituted pyrazole derivative
US20100249164A1 (en) 2007-10-31 2010-09-30 Renger John J Modulation of sleep with nr2b receptor antagonists
NZ588698A (en) * 2008-03-27 2012-06-29 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
US8293917B2 (en) 2008-05-06 2012-10-23 Boehringer Ingelheim International Gmbh Pyrazole compounds as CCR1 antagonists
BRPI0917540A2 (pt) 2008-08-05 2015-11-17 Daiichi Sankyo Co Ltd composto, sal farmacologicamente aceitavél, composição farmacêutica, e, uso de um composto ou sal farmacologicamente aceitável
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
PH12012502046A1 (en) 2010-04-14 2017-07-26 Array Biopharma Inc 5,7-substituted~imidazo[1,2-c]pyrimidines as inhibitors of jak kinases
US9434743B2 (en) * 2012-03-02 2016-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
WO2014124651A1 (en) 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
PT3180329T (pt) 2014-08-15 2020-06-08 Janssen Pharmaceuticals Inc Triazóis como inibidores do recetor nr2b
LT3319963T (lt) 2015-07-09 2020-03-25 Janssen Pharmaceutica Nv Pakeistieji 4-azaindolai ir jų, kaip glun2b receptoriaus moduliatorių, panaudojimas
CA3014314A1 (en) 2016-02-10 2017-08-17 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途

Also Published As

Publication number Publication date
EP3180315A1 (en) 2017-06-21
HUE049278T2 (hu) 2020-09-28
USRE49517E1 (en) 2023-05-02
US20170275254A1 (en) 2017-09-28
WO2016025918A1 (en) 2016-02-18
JP2017525700A (ja) 2017-09-07
ES2791252T3 (es) 2020-11-03
PL3180315T3 (pl) 2020-09-07
DK3180315T3 (da) 2020-04-06
EP3180315B1 (en) 2020-03-18
PT3180315T (pt) 2020-05-27
US10155727B2 (en) 2018-12-18

Similar Documents

Publication Publication Date Title
JP6618525B2 (ja) ピラゾール類
JP6605020B2 (ja) Ｎｒ２ｂ受容体阻害剤としてのトリアゾール
JP4740115B2 (ja) 置換ピラゾール
TWI428334B (zh) 作為５-ｈｔ6拮抗劑之磺醯基吡唑及磺醯基吡唑啉的甲脒衍生物
CN110234638B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
JP2021510151A (ja) アルツハイマー病等のタウ凝集体に関連する障害の治療、緩和、または予防のための１，３，４，５−テトラヒドロ−２ｈ−ピリド（４，３−ｂ）インドール誘導体
JP4740116B2 (ja) 精神疾患および神経障害の処置のための５−ｈｔ受容体アンタゴニスト
JP2011513295A (ja) インダゾール誘導体
EP2509978A1 (en) Azocyclic inhibitors of fatty acid amide hydrolase
JP2011153144A (ja) 置換ピラゾール化合物
JP2009528318A (ja) シグマ受容体化合物
JP4833832B2 (ja) ピラゾール化合物
EP3055293A1 (en) Diarylalkylamine rev-erb antagonists and their use as medicaments
MX2011001070A (es) Nuevos derivados de difenil 1,2,3-triazol utiles como moduladores de los receptores de acetilcolina nicotinicos.
WO2016067143A1 (en) N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
JP6941235B2 (ja) イミダゾピリジン誘導体及び薬物としてのその使用
JP6656246B2 (ja) プロキネチシン介在消化器疾患を治療するためのスルホニルピペリジン誘導体及びその使用
JP2013231000A (ja) ３−アミノメチルピラゾール誘導体
KR20100072037A (ko) 칸나비노이드 ｃｂ₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1ｈ)-피라졸
JP2010534231A (ja) デュシェンヌ型筋ジストロフィーを治療するための化合物
JP2025504889A (ja) エモパミル結合タンパク質阻害剤及びその使用
HK40014240B (zh) 杂芳基苯氧基苯甲酰胺kappa阿片类配体
HK1142076A (en) 5-aryl-4,5-dihydro-(1h)pyrazoles as cannabinoid cb1 receptor agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180813

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191112

R150 Certificate of patent or registration of utility model

Ref document number: 6618525

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250